FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (NASDAQ:MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, announced the establishment of the first global high intensity focused ultrasound (“HIFU”) Prostate Cancer Treatment Clinical Registry. The HIFU Clinical Registry is solely for Sonablate 500 (“SB500”) users from around the world. Current and future surgeons relying on the SB500 for the most effective prostate cancer therapy will be able to access the HIFU Clinical Registry for important medical information relating to completed patient procedures. As a repository for data from all SB500 users from centers around the world, more comprehensive information will be available for research and analysis. This data will be used for the production of reports for publication in medical journals and for use in other mediums to promote the SB500 as the most efficacious and patient-friendly prostate cancer treatment.
